JANUARY 21, 2009--Cambridge Research (CRi, Woburn, MA) and VisEn Medical (Bedford, MA) have signed a non-exclusive agreement enabling CRi to distribute VisEn's proprietary portfolio of fluorescent imaging contrast agents and labels for radiology within the US, Canada, Mexico, Central America and the Caribbean. The distribution partnership is designed to broaden and extend fluorescence in vivo imagingtechnologies, applications and standards in research and pharmaceutical development.
VisEn offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways in vivo, with several more new agents expected for launch in 2009. Key research areas enabled by the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease, and pulmonary diseases, all in the context of the living animal.
VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag fluorescence labeling dyes for custom in vivo agent development, and its NanoSpark in vivo labeling nanoparticles, all designed and optimized for superior brightness, biocompatibility, stability and results in in vivo imaging. VisEn's agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro system with its proprietary multispectral imaging technology. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.
"With a deep heritage in multi-spectral fluorescence in vivo imaging and fluorescence microscopy imaging systems, we have built a significant customer base with a broad range of applications in life science research today. Bringing VisEn's fluorescent in vivo agents and labels to our Maestro multispectral fluorescence imaging system customers now expands the breadth of research for them, and for CRi," said George Abe, CRi's President and CEO.
"With several applications already developed in oncology and inflammation using the VisEn agents on the Maestro platforms, we look forward to working with CRi in rapidly expanding today's research areas in fluorescence imaging in vivo," said Kirtland Poss, President and CEO of VisEn Medical.
Posted by Barbara G. Goode, [email protected].